A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

NCT06053099 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer
EGFR Activating Mutation
EGFR DEL19
EGFR L858R

Interventions

OTHER: Plasma ctDNA
OTHER: FFPE blocks

Sponsor

Intergroupe Francophone de Cancerologie Thoracique